The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for

Myelodysplastic syndrome (MDS) is a challenging and complicated disease with median outcomes ranging from 5.3 years in patients with lower-risk disease to just 8.4 months in the very high-risk population.1,2 However, newly approved agents entering the armamentarium are providing better outcomes for patients with MDS, especially for those with lower-risk disease.

We are pleased to present this Summary for Patients of the Seventh AAMDSIF International Bone Marrow
Failure Scientific Symposium held virtually on July 15, 16 & 17, 2020. Our Symposium brought together many

In this issue of Blood, Nagata et al show for the first time that machine learning (ML) algorithms can discern patterns and identify diagnostically and prognostically relevant associations between genetic variants and cytomorphological changes in

Delaying treatment for up to 7 days so that genomic data can be utilized to inform a personalized treatment approach is safe, feasible, and can improve overall survival in patients with

Advances in Hematologic Malignancies
Issue 12, Summer 2020
— R. Coleman Lindsley, MD, PhD

Key Points
Adult patients with hematologic malignancy and COVID-19 have a 34% risk of death, while pediatric patients have a 4% risk of death.

Patients on systemic anti-cancer therapy had a similar risk of death to patients on no treatment (RR 1.17, 95% CI 0.83-1.64).

By Mikkael A. Sekeres, M.D.
Oct. 7, 2020

One of the many perplexing issues with COVID-19 is that it affects people so differently. That has researchers trying to explain why some folks bounce right back from the virus, or don’t even know they have it—while others become critically ill. Now, two NIH-funded studies suggest that one reason some otherwise healthy people become gravely ill may be previously unknown trouble spots in their immune systems, which hamper their ability to fight the virus.